A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies

December 12, 2023 updated by: Deciphera Pharmaceuticals LLC

A Multicenter Phase 1, Open-Label Study of DCC-2618 to Assess Safety, Tolerability, Efficacy, and Pharmacokinetics in Patients With Advanced Malignancies

This is a Phase 1, open-label, first-in-human (FIH) dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of DCC-2618, administered orally (PO), in adult patients with advanced malignancies. The study consists of 2 parts, a dose-escalation phase, and an expansion phase. All active patients (from both dose-escalation and expansion phases) will then transition into an extension phase.

Study Overview

Study Type

Interventional

Enrollment (Actual)

282

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Toronto, Canada, M5G IX5
        • Princess Margaret Cancer Centre (GIST, other solid tumors)
      • Aachen, Germany, 52074
        • Uniklinik RWTH Aachen (mastocytosis, GIST, and other solid tumors)
      • Berlin, Germany, 13125
        • HELIOS Klinikum Berlin-Buch (GIST, and other solid tumors)
      • Essen, Germany, 45147
        • Essen University Hospital (mastocytosis, GIST, and other solid tumors)
      • Freiburg, Germany, 79106
        • Freiburg University Hospital (mastocytosis, and other solid tumors)
      • Mannheim, Germany, 68167
        • University Medical Centre Mannheim (mastocytosis)
      • Verona, Italy, 37134
        • University Hospital of Verona (mastocytosis)
      • Leiden, Netherlands, 2333
        • Leiden University Medical Center (GIST and other solid tumors)
      • London, United Kingdom, SE1 9RT
        • Guy's Hospital (mastocytosis only)
      • London, United Kingdom, SW3 6JJ
        • Royal Marsden Hospital (GIST, glial malignancies, other solid tumors)
    • Arizona
      • Scottsdale, Arizona, United States, 85258
        • Honor Health (GIST, mastocytosis, other solid tumors)
    • California
      • Los Angeles, California, United States, 90024
        • UCLA Hematology Center (mastocytosis)
      • Los Angeles, California, United States, 90095
        • UCLA (glial malignancies only)
      • Palo Alto, California, United States, 94304
        • Stanford University Comprehensive Cancer Center (GIST)
      • Palo Alto, California, United States, 94305
        • Stanford University Hematology Clinic (mastocytosis)
      • San Francisco, California, United States, 94143
        • UCSF (glial malignancies only)
    • Florida
      • Jacksonville, Florida, United States, 32224
        • Mayo Clinic (GIST, mastocytosis, glial malignancies, other solid tumors)
      • Miami, Florida, United States, 33136
        • University of Miami (GIST, mastocytosis, glial malignancies, other solid tumors)
    • Massachusetts
      • Boston, Massachusetts, United States, 02215
        • Dana Farber Cancer Institute (GIST, mastocytosis, glial malignancies, other solid tumors)
    • New York
      • New York, New York, United States, 10032
        • Colombia University Medical Center (mastocytosis)
      • New York, New York, United States, 10065
        • Memorial Sloan Kettering Cancer Center (GIST, mastocytosis, glial malignancies, other solid tumors)
    • Oregon
      • Portland, Oregon, United States, 97239
        • OHSU (GIST & mastocytosis only)
    • Pennsylvania
      • Philadelphia, Pennsylvania, United States, 19111
        • Fox Chase Cancer Center (GIST only)
    • Texas
      • Houston, Texas, United States, 77030
        • MD Anderson Cancer Center (GIST, mastocytosis, glial malignancies, other solid tumors)
    • Utah
      • Salt Lake City, Utah, United States, 84103
        • Huntsman Cancer Institute (GIST, mastocytosis, glial malignancies, other solid tumors)
    • Virginia
      • Richmond, Virginia, United States, 23219
        • Virginia Commonwealth University School of Medicine (mastocytosis)

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria (Escalation and Expansion Phases)

Patients must meet the following criteria to be eligible to enroll in the study:

  1. Male or female patients ≥18 years of age.
  2. Patients must have histologically confirmed solid tumors or hematologic malignancies. Eligible patients include the following:

    1. GIST patients must have a KIT and PDGFRA mutation and must have progressed on or had an intolerability to at least 1 line of systemic anticancer therapy.
    2. SM patients must have a confirmed diagnosis of advanced SM according to 2016 World Health Organization (WHO) criteria for SM and must have documented KIT mutant disease. Patients with imatinib-sensitive KIT mutations must have progressed on or were intolerant to a tyrosine kinase inhibitor. Patients with advanced SM must present with at least 1 eligible C-Finding (organ damage) per 2013 International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis consensus response criteria; please see below for MCL exception.

    Advanced SM includes:

    i. Aggressive SM (ASM)

    ii. SM with associated hematologic neoplasm (SM-AHN), wherein the AHN does not require immediate alternative therapy. AHNs that are eligible include: low grade myelodysplastic syndrome (MDS) with a high SM burden who require treatment for SM only, myeloproliferative neoplasms (MPN), MDS/MPN, unclassifiable MDS, and HES/CEL.

    iii. MCL

    • Patients with histopathologically-confirmed MCL without a C-finding are eligible.

    iv. Symptomatic SSM

    • By definition, SSM patients must have at least 2 B-findings, and clinically significant symptom burden (eg, flushing, diarrhea, etc.) despite maximal treatment with approved agents to treat mediator symptoms, such as antihistamines and cromolyn sodium.

    v. Patients with hematologic malignancies featuring clonal expansion of eosinophils driven by genomic alterations of KIT or PDGFRA (eg, HES or CEL) are eligible if they have progressed on or are intolerant of imatinib therapy. Patients with de novo imatinib resistant mutations, such as but not limited to KIT D816V or PDGFRA D842V, are eligible without prior imatinib therapy.

    c. Malignant glioma patients with genomic alterations potentially conferring sensitivity to DCC-2618 including, but not limited to, amplification and/or mutations of PDGFRA and/or KIT.

    Other solid tumor patients that have alterations in genes encoding kinases that are targets of DCC-2618. This includes:

    • Melanoma
    • Soft tissue sarcoma patients (including but not limited to: malignant peripheral nerve sheath tumors (MPNST), desmoplastic small round cell tumors (DSRCT), and dermatofibrosarcoma protuberans tumors (DFSP)
    • Other solid tumor patients (non-melanoma, non-STS; specifically germ-cell, penile, and non-small cell lung carcinoma)
    • Renal impairment cohort
  3. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of ≤2.
  4. Adequate organ function and bone marrow function.

Exclusion Criteria (Escalation and Expansion Phases)

Patients meeting any of the following criteria will be excluded from the study:

  1. GIST patients with wild type or unknown KIT or PDGFRA status.
  2. Patients with SM or other hematologic malignancies will be excluded if the following apply:

    1. SM patients with neutropenia accompanied by fever or infection, or thrombocytopenia associated with clinically significant bleeding.

      • Patients with an infection that is well controlled with antibiotics are eligible if there is an immediate need for treatment.

    2. SM-AHN patients diagnosed with:

    i. SM with MDS who require treatment for MDS. ii. Patients requiring immediate treatment for AHN.

    c. Patients with leukemias, with the exception of MCL and CEL, that have progressed after imatinib.

    d. Eosinophilic myeloproliferative neoplasm patients: i. Lacking a mutation that is a known target of DCC-2618.

  3. Prior or concurrent malignancy whose natural history or treatment have the potential to interfere with the safety or efficacy assessment of DCC-2618. Patients receiving adjuvant cancer treatment are not eligible if those medications are potentially active against GIST or excluded per protocol.
  4. New York Heart Association class III and IV heart disease, active ischemia or any other uncontrolled cardiac condition such as angina pectoris, clinically significant cardiac arrhythmia requiring therapy, uncontrolled hypertension or congestive heart failure.
  5. Arterial thrombotic or embolic events such as cerebrovascular accident (including ischemic attacks) or hemoptysis within 6 months before start of study drug.
  6. Venous thrombotic events (eg, deep vein thrombosis) or pulmonary arterial events (eg, pulmonary embolism) within the 3 months before start of study drug. Patients with venous thrombotic events ≥3 months before start of study drug on stable anticoagulation therapy are eligible.
  7. Baseline prolongation of the rate-corrected QT interval based on repeated demonstration of QT interval corrected by Fridericia's formula (QTcF) >450 ms in males or >470 ms in females or history of long QT interval corrected (QTc) syndrome.
  8. Left ventricular ejection fraction (LVEF) <50% or below the lower limit of normal (whichever is higher).
  9. Major surgery within 4 weeks of the first dose of study drug; following major surgeries >4 weeks prior to the first dose of study drug, all surgical wounds must be healed and free of infection or dehiscence.
  10. Any other clinically significant comorbidities.
  11. Illnesses that could affect oral absorption.
  12. Known human immunodeficiency virus or active hepatitis C infection only if the patient is taking per protocol prohibited medications, active hepatitis B, or active hepatitis C infection.
  13. If female, the patient is pregnant or lactating.
  14. Known allergy or hypersensitivity to any component of the investigational drug product. Patients with history of Stevens-Johnson syndrome on a prior tyrosine kinase inhibitor (TKI) are excluded.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Escalation
Escalation Phase: DCC-2618 tablets in escalating dose cohorts given orally BID (twice daily) every 12 hours or once daily (QD) for repeated 28-day cycles. Participants may continue to receive study drug until discontinuation criteria are met. [Closed for Enrollment]
50 mg formulated tablets
Other Names:
  • ripretinib
10 mg and 50 mg formulated tablets
Other Names:
  • ripretinib
Experimental: Expansion Cohort 1
150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with GIST who have received 3 prior therapies. [Closed for Enrollment]
50 mg formulated tablets
Other Names:
  • ripretinib
10 mg and 50 mg formulated tablets
Other Names:
  • ripretinib
Experimental: Expansion Cohort 2
150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with GIST who have received 4 prior therapies. [Closed for Enrollment]
50 mg formulated tablets
Other Names:
  • ripretinib
10 mg and 50 mg formulated tablets
Other Names:
  • ripretinib
Experimental: Expansion Cohort 3
150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with GIST who have received at least one prior therapy and no more than 2 prior therapies. [Closed for Enrollment]
50 mg formulated tablets
Other Names:
  • ripretinib
10 mg and 50 mg formulated tablets
Other Names:
  • ripretinib
Experimental: Expansion Cohort 4
150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with systemic mastocytosis and other hematologic malignancies.[Closed for Enrollment]
50 mg formulated tablets
Other Names:
  • ripretinib
10 mg and 50 mg formulated tablets
Other Names:
  • ripretinib
Experimental: Expansion Cohort 5
150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with malignant gliomas.[Closed for Enrollment]
50 mg formulated tablets
Other Names:
  • ripretinib
10 mg and 50 mg formulated tablets
Other Names:
  • ripretinib
Experimental: Expansion Cohort 6
150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with other solid tumors. [Closed for Enrollment]
50 mg formulated tablets
Other Names:
  • ripretinib
10 mg and 50 mg formulated tablets
Other Names:
  • ripretinib
Experimental: Expansion Cohort 7
150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with melanomas. [Closed for Enrollment]
50 mg formulated tablets
Other Names:
  • ripretinib
10 mg and 50 mg formulated tablets
Other Names:
  • ripretinib
Experimental: Expansion Cohort 8
150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with soft tissue sarcomas.[Closed for Enrollment]
50 mg formulated tablets
Other Names:
  • ripretinib
10 mg and 50 mg formulated tablets
Other Names:
  • ripretinib
Experimental: Expansion Cohort 9
150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with germ cell, penile cancer and non-small cell lung carcinoma (NSCLC). [Closed for Enrollment]
50 mg formulated tablets
Other Names:
  • ripretinib
10 mg and 50 mg formulated tablets
Other Names:
  • ripretinib
Experimental: Expansion Cohort 10
150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with GIST and other solid tumors with renal impairment. [Closed for Enrollment]
50 mg formulated tablets
Other Names:
  • ripretinib
10 mg and 50 mg formulated tablets
Other Names:
  • ripretinib
Experimental: Extension Cohort
150 mg DCC-2618 given once daily in repeated 28-day cycles for active patients from the Escalation and Extension Phases.
50 mg formulated tablets
Other Names:
  • ripretinib
10 mg and 50 mg formulated tablets
Other Names:
  • ripretinib

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Safety/tolerability of oral DCC-2618: incidence of adverse events
Time Frame: Approximately 24 months
Dose limiting toxicities, AEs, SAEs, discontinuation of drug due to toxicity, physical exams and ECOG PS, ophthalmologic examinations, changes from baseline in laboratory parameters, electrocardiograms, LVEF, and vital signs.
Approximately 24 months
Determination of the Maximum Tolerated Dose and the Recommended Phase 2 Dose
Time Frame: 18 months
18 months
Expansion Phase: Assess Antitumor Activity of DCC-2618 in all diseases
Time Frame: Approximately 24 months
Objective response rate (ORR); Disease control rate (DCR)
Approximately 24 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Determine the PK profile of oral DCC-2618
Time Frame: Predose and up to 24 hours postdose (Cycle = 28 Days)
Predose and up to 24 hours postdose (Cycle = 28 Days)
Escalation Phase: Assess Antitumor Activity of DCC-2618 in patients with advanced malignancies
Time Frame: Approximately 24 months
Objective response rate (ORR); Disease control rate (DCR)
Approximately 24 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Deciphera Pharmaceuticals, LLC, Deciphera Pharmaceuticals LLC

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 1, 2015

Primary Completion (Actual)

April 29, 2022

Study Completion (Actual)

April 29, 2022

Study Registration Dates

First Submitted

October 5, 2015

First Submitted That Met QC Criteria

October 6, 2015

First Posted (Estimated)

October 8, 2015

Study Record Updates

Last Update Posted (Estimated)

December 13, 2023

Last Update Submitted That Met QC Criteria

December 12, 2023

Last Verified

December 1, 2023

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Gastrointestinal Stromal Tumors

Clinical Trials on DCC-2618

3
Subscribe